Table II.
Case | CD21 | CD35 | CD23 | D2 40 | CXCL 13 | S-100 | Vimentin | EMA | CK | CD163 | LCA | CD1a | CD68 | CD34 | CD3 | CD20 | Ki-67 (%) | EBER |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | + | +++ | +++ | + | − | − | + | − | − | +b | +b | 0 | 0 | 0 | 0 | 0 | 35 | − |
2 | ++ | + | +++ | + | − | − | + | − | − | +b | +b | 0 | 0 | − | 0 | 0 | 40 | − |
3 | + | + | ++ | + | − | − | + | + | + | +b | +b | − | − | 0 | − | − | 30 | − |
D2-40, podoplanin; EMA, epithelial membrane antigen; CK, cytokeratin; LCA, leukocyte common antigen; +, positive; −, negative; 0, not done; +b, positive for background cells, negative for tumor cells.